{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T01:35:08Z","timestamp":1793928908465,"version":"4.8.0"},"reference-count":129,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Association for Cancer Research (AIRC)"},{"name":"Fondo di Ricerca di Ateneo 2018-University of Trieste"},{"name":"Italian Ministry of Health (Ricerca Corrente)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Nanoparticle-based therapies have been proposed in oncology research using various delivery methods to increase selectivity toward tumor tissues. Enhanced drug delivery through nanoparticle-based therapies could improve anti-tumor efficacy and also prevent drug resistance. However, there are still problems to overcome, such as the main biological interactions of nanocarriers. Among the various nanostructures for drug delivery, drug delivery based on polymeric nanoparticles has numerous advantages for controlling the release of biological factors, such as the ability to add a selective targeting mechanism, controlled release, protection of administered drugs, and prolonging the circulation time in the body. In addition, the functionalization of nanoparticles helps to achieve the best possible outcome. One of the most promising applications for nanoparticle-based drug delivery is in the field of onco-hematology, where there are many already approved targeted therapies, such as immunotherapies with monoclonal antibodies targeting specific tumor-associated antigens; however, several patients have experienced relapsed or refractory disease. This review describes the major nanocarriers proposed as new treatments for hematologic cancer, describing the main biological interactions of these nanocarriers and the related limitations of their use as drug delivery strategies.<\/jats:p>","DOI":"10.3390\/pharmaceutics14091965","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T04:49:22Z","timestamp":1663562962000},"page":"1965","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Nanocarriers as a Delivery Platform for Anticancer Treatment: Biological Limits and Perspectives in B-Cell Malignancies"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0793-0118","authenticated-orcid":false,"given":"Sara","family":"Bozzer","sequence":"first","affiliation":[{"name":"Department of Life Sciences, University of Trieste, 34127 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8668-7621","authenticated-orcid":false,"given":"Michele","family":"Dal Bo","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4646-0032","authenticated-orcid":false,"given":"Maria Cristina","family":"Grimaldi","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, University of Trieste, 34127 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5323-4762","authenticated-orcid":false,"given":"Giuseppe","family":"Toffoli","sequence":"additional","affiliation":[{"name":"Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), 33081 Aviano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3079-4019","authenticated-orcid":false,"given":"Paolo","family":"Macor","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, University of Trieste, 34127 Trieste, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jconrel.2021.06.025","article-title":"Cancer immunotherapy from biology to nanomedicine","volume":"336","author":"Abdelbaky","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"120438","DOI":"10.1016\/j.ijpharm.2021.120438","article-title":"Advanced nanomedicine and cancer: Challenges and opportunities in clinical translation","volume":"599","author":"Girotti","year":"2021","journal-title":"Int. J. Pharm."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Damasco, J.A., Ravi, S., Perez, J.D., Hagaman, D.E., and Melancon, M.P. (2020). Understanding Nanoparticle Toxicity to Direct a Safe-by-Design Approach in Cancer Nanomedicine. Nanomaterials, 10.","DOI":"10.3390\/nano10112186"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.yrtph.2012.11.007","article-title":"Considerations on the EU definition of a nanomaterial: Science to support policy making","volume":"65","author":"Bleeker","year":"2013","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/nbt872","article-title":"The \u2018right\u2019 size in nanobiotechnology","volume":"21","author":"Whitesides","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1097\/CCM.0b013e3181921349","article-title":"Toward theragnostics","volume":"37","author":"Pene","year":"2009","journal-title":"Crit. Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.copbio.2013.02.020","article-title":"Recent progress in nanomedicine: Therapeutic, diagnostic and theranostic applications","volume":"24","author":"Rizzo","year":"2013","journal-title":"Curr. Opin. Biotechnol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/nn900002m","article-title":"Impact of nanotechnology on drug delivery","volume":"3","author":"Farokhzad","year":"2009","journal-title":"ACS Nano"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.3324\/haematol.2018.211011","article-title":"The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models","volume":"104","author":"Hicks","year":"2019","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s11033-020-06073-3","article-title":"Acute lymphoid leukemia etiopathogenesis","volume":"48","author":"Fujita","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(18)30909-4","article-title":"Estimating the total incidence of global childhood cancer: A simulation-based analysis","volume":"20","author":"Ward","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1470-2045(17)30186-9","article-title":"International incidence of childhood cancer, 2001-10: A population-based registry study","volume":"18","author":"Colombet","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cbpa.2005.06.001","article-title":"Nanovector therapeutics","volume":"9","author":"Ferrari","year":"2005","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.nano.2005.10.003","article-title":"Nanomedicine and nanotoxicology: Two sides of the same coin","volume":"1","author":"Kagan","year":"2005","journal-title":"Nanomedicine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/nrc.2016.108","article-title":"Cancer nanomedicine: Progress, challenges and opportunities","volume":"17","author":"Shi","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"17024","DOI":"10.1038\/natrevmats.2017.24","article-title":"Rethinking cancer nanotheranostics","volume":"2","author":"Chen","year":"2017","journal-title":"Nat. Rev. Mater."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1021\/mp200394t","article-title":"Nanomedicine(s) under the microscope","volume":"8","author":"Duncan","year":"2011","journal-title":"Mol. Pharm."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.apsb.2020.12.018","article-title":"Biological drug and drug delivery-mediated immunotherapy","volume":"11","author":"Xiao","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nnano.2007.387","article-title":"Nanocarriers as an emerging platform for cancer therapy","volume":"2","author":"Peer","year":"2007","journal-title":"Nat. Nanotechnol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.tibtech.2016.07.006","article-title":"Breaking Down the Barriers to Precision Cancer Nanomedicine","volume":"35","author":"Jiang","year":"2017","journal-title":"Trends Biotechnol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Thi, T.T.H., Suys, E.J.A., Lee, J.S., Nguyen, D.H., Park, K.D., and Truong, N.P. (2021). Lipid-Based Nanoparticles in the Clinic and Clinical Trials: From Cancer Nanomedicine to COVID-19 Vaccines. Vaccines, 9.","DOI":"10.3390\/vaccines9040359"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/0014-5793(73)80394-1","article-title":"Drug entrapment in liposomes","volume":"36","author":"Gregoriadis","year":"1973","journal-title":"FEBS Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4068\/cmj.2021.57.1.27","article-title":"Liposomes: Biomedical Applications","volume":"57","author":"Kim","year":"2021","journal-title":"Chonnam Med. J."},{"key":"ref_25","first-page":"467","article-title":"Targeted therapy using nanotechnology: Focus on cancer","volume":"9","author":"Sanna","year":"2014","journal-title":"Int. J. Nanomed."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.colsurfb.2014.09.029","article-title":"Liposomes as carriers of hydrophilic small molecule drugs: Strategies to enhance encapsulation and delivery","volume":"123","author":"Eloy","year":"2014","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Maximilien, J., Beyazit, S., Rossi, C., Haupt, K., and Tse Sum Bui, B. (2015). Nanoparticles in Biomedical Applications. Measuring Biological Impacts of Nanomaterials, Springer.","DOI":"10.1007\/11663_2015_12"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.nantod.2013.04.006","article-title":"Anthracycline Nano-Delivery Systems to Overcome Multiple Drug Resistance: A Comprehensive Review","volume":"8","author":"Ma","year":"2013","journal-title":"Nano Today"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"16","DOI":"10.3109\/1061186X.2014.954119","article-title":"The use of ultrasound to release chemotherapeutic drugs from micelles and liposomes","volume":"23","author":"Ahmed","year":"2015","journal-title":"J. Drug Target."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.canlet.2016.01.050","article-title":"Development of highly efficient nanocarrier-mediated delivery approaches for cancer therapy","volume":"374","author":"Jeong","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1056\/NEJMra0912273","article-title":"Nanomedicine","volume":"363","author":"Kim","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1007\/s11095-016-1958-5","article-title":"Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date","volume":"33","author":"Bobo","year":"2016","journal-title":"Pharm. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jconrel.2019.07.011","article-title":"The size and composition of polymeric nanocapsules dictate their interaction with macrophages and biodistribution in zebrafish","volume":"308","author":"Peleteiro","year":"2019","journal-title":"J. Control. Release"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.4161\/hv.26796","article-title":"Polymeric nanoparticles: Potent vectors for vaccine delivery targeting cancer and infectious diseases","volume":"10","author":"Bolhassani","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/wnan.1364","article-title":"Polymeric nanoparticles: The future of nanomedicine","volume":"8","author":"Banik","year":"2016","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1021\/acs.chemrev.5b00346","article-title":"Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release","volume":"116","author":"Kamaly","year":"2016","journal-title":"Chem. Rev."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Mansoor, S., Kondiah, P.P.D., Choonara, Y.E., and Pillay, V. (2019). Polymer-Based Nanoparticle Strategies for Insulin Delivery. Polymers, 11.","DOI":"10.3390\/polym11091380"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1208\/s12249-017-0725-1","article-title":"Development of a Gastric Absorptive, Immediate Responsive, Oral Protein-Loaded Versatile Polymeric Delivery System","volume":"18","author":"Kondiah","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s11095-007-9257-9","article-title":"Chitosan reduced gold nanoparticles as novel carriers for transmucosal delivery of insulin","volume":"24","author":"Bhumkar","year":"2007","journal-title":"Pharm. Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijpharm.2018.10.068","article-title":"Enhanced oral insulin delivery via surface hydrophilic modification of chitosan copolymer based self-assembly polyelectrolyte nanocomplex","volume":"554","author":"Liu","year":"2019","journal-title":"Int J Pharm"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Elsayed, A., Al-Remawi, M., Farouk, A., and Badwan, A. (2010). Insulin-chitosan polyelectrolyte _anocomplexes: Preparation, characterization and stabilization of insulin. Sudan J. Med. Sci., 5.","DOI":"10.4314\/sjms.v5i2.57799"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"400","DOI":"10.22270\/jddt.v8i5-s.2002","article-title":"Preparation and Characterization of Chitosan Nanoparticles of Insulin for Nasal Delivery","volume":"8","author":"Sharma","year":"2018","journal-title":"J. Drug Deliv. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1208\/s12249-014-0282-9","article-title":"Development of acid-resistant alginate\/trimethyl chitosan nanoparticles containing cationic beta-cyclodextrin polymers for insulin oral delivery","volume":"16","author":"Mansourpour","year":"2015","journal-title":"AAPS PharmSciTech"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s10989-005-9010-3","article-title":"Development and Comparison of Different Nanoparticulate Polyelectrolyte Complexes as Insulin Carriers","volume":"12","author":"Sarmento","year":"2006","journal-title":"Int. J. Pept. Res. Ther."},{"key":"ref_45","first-page":"23","article-title":"Nanoemulsions coated with alginate\/chitosan as oral insulin delivery systems: Preparation, characterization, and hypoglycemic effect in rats","volume":"8","author":"Li","year":"2013","journal-title":"Int. J. Nanomed."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.actbio.2015.12.017","article-title":"Vitamin B12 functionalized layer by layer calcium phosphate nanoparticles: A mucoadhesive and pH responsive carrier for improved oral delivery of insulin","volume":"31","author":"Verma","year":"2016","journal-title":"Acta Biomater."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.matlet.2016.10.117","article-title":"Oral delivery of insulin using CaCO3-based composite nanocarriers with hyaluronic acid coatings","volume":"188","author":"Liu","year":"2017","journal-title":"Mater. Lett."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1208\/s12249-012-9807-2","article-title":"Insulin-loaded pH-sensitive hyaluronic acid nanoparticles enhance transcellular delivery","volume":"13","author":"Han","year":"2012","journal-title":"AAPS PharmSciTech"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jconrel.2016.04.012","article-title":"Dual chitosan\/albumin-coated alginate\/dextran sulfate nanoparticles for enhanced oral delivery of insulin","volume":"232","author":"Lopes","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jconrel.2016.02.031","article-title":"Dextran-b-poly(lactide-co-glycolide) polymersome for oral delivery of insulin: In vitro and in vivo evaluation","volume":"227","author":"Alibolandi","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2007.05.019","article-title":"Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles","volume":"122","author":"Chalasani","year":"2007","journal-title":"J. Control. Release"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/10601320903458556","article-title":"Designing Gelatin Nanocarriers as a Swellable System for Controlled Release of Insulin: AnIn-VitroKinetic Study","volume":"47","author":"Goswami","year":"2009","journal-title":"J. Macromol. Sci. Part A"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00592-011-0356-z","article-title":"Experiment on the feasibility of using modified gelatin nanoparticles as insulin pulmonary administration system for diabetes therapy","volume":"49","author":"Zhao","year":"2012","journal-title":"Acta Diabetol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1463-1326.2011.01546.x","article-title":"Preparation, characterization and in vivo evaluation of pH-sensitive oral insulin-loaded poly(lactic-co-glycolicacid) nanoparticles","volume":"14","author":"Yang","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1166\/jbn.2016.2176","article-title":"Bioengineering Strategies for the Treatment of Type I Diabetes","volume":"12","author":"Liu","year":"2016","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1166\/jbn.2013.1607","article-title":"Insulin-loaded poly(epsilon-caprolactone) nanoparticles: Efficient, sustained and safe insulin delivery system","volume":"9","author":"Teixeira","year":"2013","journal-title":"J. Biomed. Nanotechnol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jconrel.2006.10.023","article-title":"Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats","volume":"117","author":"Damge","year":"2007","journal-title":"J. Control. Release"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijbiomac.2011.10.006","article-title":"Preparation and characterization of chitosan-polyvinyl alcohol blend hydrogels for the controlled release of nano-insulin","volume":"50","author":"Zu","year":"2012","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1021\/mp5003653","article-title":"Molecular mechanism of poly(vinyl alcohol) mediated prevention of aggregation and stabilization of insulin in nanoparticles","volume":"12","author":"Rawat","year":"2015","journal-title":"Mol. Pharm."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1016\/j.biomaterials.2010.01.042","article-title":"Enteric-coated capsules filled with freeze-dried chitosan\/poly(gamma-glutamic acid) nanoparticles for oral insulin delivery","volume":"31","author":"Sonaje","year":"2010","journal-title":"Biomaterials"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jconrel.2008.08.020","article-title":"Multi-ion-crosslinked nanoparticles with pH-responsive characteristics for oral delivery of protein drugs","volume":"132","author":"Lin","year":"2008","journal-title":"J. Control. Release"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.msec.2016.08.083","article-title":"Preparation of chitosan-based multifunctional nanocarriers overcoming multiple barriers for oral delivery of insulin","volume":"70","author":"Li","year":"2017","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jconrel.2004.11.018","article-title":"Release kinetics of hydrophobic and hydrophilic model drugs from pluronic F127\/poly(lactic acid) nanoparticles","volume":"103","author":"Xiong","year":"2005","journal-title":"J. Control. Release"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1158\/1535-7163.MCT-06-0141","article-title":"Nanotechnology in cancer therapeutics: Bioconjugated nanoparticles for drug delivery","volume":"5","author":"Sinha","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"ref_65","first-page":"3351","article-title":"Toxicity evaluation of biodegradable chitosan nanoparticles using a zebrafish embryo model","volume":"6","author":"Hu","year":"2011","journal-title":"Int. J. Nanomed."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ijpharm.2013.08.041","article-title":"Micro- and nanobubbles: A versatile non-viral platform for gene delivery","volume":"456","author":"Cavalli","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijbiomac.2017.12.078","article-title":"A review on chitosan and its nanocomposites in drug delivery","volume":"109","author":"Ali","year":"2018","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/anie.200802585","article-title":"Nanomedicine--challenge and perspectives","volume":"48","author":"Riehemann","year":"2009","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Sharma, A.K., Gupta, L., and Gupta, U. (2017). Nanoparticles as nucleic acid delivery vectors. Advances in Nanomedicine for the Delivery of Therapeutic Nucleic Acids, Elsevier.","DOI":"10.1016\/B978-0-08-100557-6.00002-X"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jconrel.2016.11.015","article-title":"To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?","volume":"244","author":"Danhier","year":"2016","journal-title":"J. Control. Release"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.3389\/fphar.2018.01260","article-title":"PLGA-Based Nanoparticles in Cancer Treatment","volume":"9","author":"Rezvantalab","year":"2018","journal-title":"Front. Pharmacol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"517","DOI":"10.7314\/APJCP.2014.15.2.517","article-title":"PLGA-based nanoparticles as cancer drug delivery systems","volume":"15","author":"Akbarzadeh","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"39823","DOI":"10.1039\/C6RA05742J","article-title":"Poly(vinyl alcohol): Review of its promising applications and insights into biodegradation","volume":"6","year":"2016","journal-title":"RSC Adv."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0168-3659(02)00127-X","article-title":"Residual polyvinyl alcohol associated with poly (d,l-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake","volume":"82","author":"Sahoo","year":"2002","journal-title":"J. Control. Release"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2133\/dmpk.DMPK-10-RV-062","article-title":"Mechanisms of drug toxicity and relevance to pharmaceutical development","volume":"26","author":"Guengerich","year":"2011","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Houshmand, M., Garello, F., Circosta, P., Stefania, R., Aime, S., Saglio, G., and Giachino, C. (2020). Nanocarriers as Magic Bullets in the Treatment of Leukemia. Nanomaterials, 10.","DOI":"10.3390\/nano10020276"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40169-017-0175-0","article-title":"Cancer nanomedicine: A review of recent success in drug delivery","volume":"6","author":"Tran","year":"2017","journal-title":"Clin. Transl. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1039\/D0BM02221G","article-title":"Strategies for the design of nanoparticles: Starting with long-circulating nanoparticles, from lab to clinic","volume":"9","author":"Wang","year":"2021","journal-title":"Biomater. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2015.02.003","article-title":"Going beyond the liver: Progress and challenges of targeted delivery of siRNA therapeutics","volume":"203","author":"Lorenzer","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4638192","DOI":"10.1155\/2020\/4638192","article-title":"The Dual Role of the Liver in Nanomedicine as an Actor in the Elimination of Nanostructures or a Therapeutic Target","volume":"2020","author":"Baboci","year":"2020","journal-title":"J. Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jconrel.2014.05.036","article-title":"State-of-the-art in design rules for drug delivery platforms: Lessons learned from FDA-approved nanomedicines","volume":"187","author":"Dawidczyk","year":"2014","journal-title":"J. Control. Release"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"715","DOI":"10.2217\/nnm.11.19","article-title":"Nanoparticle PEGylation for imaging and therapy","volume":"6","author":"Jokerst","year":"2011","journal-title":"Nanomedicine"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2217\/nnm.10.23","article-title":"Understanding and overcoming major barriers in cancer nanomedicine","volume":"5","author":"Nie","year":"2010","journal-title":"Nanomedicine"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1039\/C6CS00636A","article-title":"Cellular uptake of nanoparticles: Journey inside the cell","volume":"46","author":"Behzadi","year":"2017","journal-title":"Chem. Soc. Rev."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12551-012-0072-0","article-title":"Toward a molecular understanding of nanoparticle-protein interactions","volume":"4","author":"Treuel","year":"2012","journal-title":"Biophys. Rev."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.trac.2019.05.039","article-title":"Role of protein corona in the biological effect of nanomaterials: Investigating methods","volume":"118","author":"Zeng","year":"2019","journal-title":"TrAC Trends Anal. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s13346-020-00745-0","article-title":"Unveiling the pitfalls of the protein corona of polymeric drug nanocarriers","volume":"10","author":"Berrecoso","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.2147\/IJN.S129300","article-title":"Protein corona: A new approach for nanomedicine design","volume":"12","author":"Nguyen","year":"2017","journal-title":"Int. J. Nanomed."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Li, Y., and Lee, J.S. (2020). Insights into Characterization Methods and Biomedical Applications of Nanoparticle-Protein Corona. Materials, 13.","DOI":"10.3390\/ma13143093"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"199","DOI":"10.2174\/9781681084930117020011","article-title":"How does \u201cProtein Corona\u201d Affect the In Vivo Efficiency of Polymeric Nanoparticles? State of Art","volume":"2","author":"Pederzoli","year":"2017","journal-title":"Front. Nanomed."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Lomis, N., Westfall, S., Farahdel, L., Malhotra, M., Shum-Tim, D., and Prakash, S. (2016). Human Serum Albumin Nanoparticles for Use in Cancer Drug Delivery: Process Optimization and In Vitro Characterization. Nanomaterials, 6.","DOI":"10.3390\/nano6060116"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3667","DOI":"10.7150\/thno.19365","article-title":"Strategies for Preparing Albumin-based Nanoparticles for Multifunctional Bioimaging and Drug Delivery","volume":"7","author":"An","year":"2017","journal-title":"Theranostics"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.biomaterials.2018.07.024","article-title":"Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solid tumors","volume":"180","author":"Hyun","year":"2018","journal-title":"Biomaterials"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jconrel.2014.12.030","article-title":"Nanomedicine in cancer therapy: Challenges, opportunities, and clinical applications","volume":"200","author":"Wicki","year":"2015","journal-title":"J. Control. Release"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.addr.2012.10.002","article-title":"The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo","volume":"65","author":"Maeda","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2013.11.009","article-title":"Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology","volume":"66","author":"Bertrand","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1002\/jcp.29126","article-title":"Nanoparticles and cancer therapy: Perspectives for application of nanoparticles in the treatment of cancers","volume":"235","author":"Dolati","year":"2020","journal-title":"J. Cell. Physiol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3389\/fphar.2017.00952","article-title":"Modulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery","volume":"8","author":"Zhang","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/natrevmats.2016.14","article-title":"Analysis of nanoparticle delivery to tumours","volume":"1","author":"Wilhelm","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ejps.2012.12.006","article-title":"A review of current nanoparticle and targeting moieties for the delivery of cancer therapeutics","volume":"48","author":"Steichen","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.addr.2017.03.001","article-title":"Combination antitumor therapy with targeted dual-nanomedicines","volume":"115","author":"Dai","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"102288","DOI":"10.1016\/j.jaut.2019.05.016","article-title":"Targeting CD34(+) cells of the inflamed synovial endothelium by guided nanoparticles for the treatment of rheumatoid arthritis","volume":"103","author":"Colombo","year":"2019","journal-title":"J. Autoimmun."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/nbt.3330","article-title":"Principles of nanoparticle design for overcoming biological barriers to drug delivery","volume":"33","author":"Blanco","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"14017","DOI":"10.1021\/jp502624n","article-title":"Secondary structure of corona proteins determines the cell surface receptors used by nanoparticles","volume":"118","author":"Fleischer","year":"2014","journal-title":"J. Phys. Chem. B"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1038\/nprot.2014.139","article-title":"Quantitative profiling of the protein coronas that form around nanoparticles","volume":"9","author":"Docter","year":"2014","journal-title":"Nat. Protoc."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.1038\/s41388-021-01918-y","article-title":"B cell heterogeneity, plasticity, and functional diversity in cancer microenvironments","volume":"40","author":"Wei","year":"2021","journal-title":"Oncogene"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Cuenca, M., and Peperzak, V. (2021). Advances and Perspectives in the Treatment of B-Cell Malignancies. Cancers, 13.","DOI":"10.3390\/cancers13092266"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Hosseinkhani, N., Derakhshani, A., Kooshkaki, O., Abdoli Shadbad, M., Hajiasgharzadeh, K., Baghbanzadeh, A., Safarpour, H., Mokhtarzadeh, A., Brunetti, O., and Yue, S.C. (2020). Immune Checkpoints and CAR-T Cells: The Pioneers in Future Cancer Therapies?. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21218305"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Van der Horst, H.J., Nijhof, I.S., Mutis, T., and Chamuleau, M.E.D. (2020). Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies. Cancers, 12.","DOI":"10.3390\/cancers12103041"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: Current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"21","DOI":"10.23736\/S0031-0808.20.04149-X","article-title":"Monoclonal antibodies in multiple myeloma","volume":"63","author":"Vozella","year":"2021","journal-title":"Panminerva Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s12274-015-0935-3","article-title":"A new approach for the treatment of CLL using chlorambucil\/hydroxychloroquine-loaded anti-CD20 nanoparticles","volume":"9","author":"Capolla","year":"2015","journal-title":"Nano Res."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.jaci.2010.02.018","article-title":"Clinical consequences of defects in B-cell development","volume":"125","author":"Vale","year":"2010","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.clml.2018.05.006","article-title":"Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies","volume":"18","author":"Herrera","year":"2018","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1042\/CS20181003","article-title":"Immunotherapy: Enhancing the efficacy of this promising therapeutic in multiple cancers","volume":"133","author":"Inthagard","year":"2019","journal-title":"Clin. Sci."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.5045\/br.2021.2020320","article-title":"Novel combination immunochemotherapy beyond CD20 for B-cell lymphomas","volume":"56","author":"Yi","year":"2021","journal-title":"Blood Res."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Panuciak, K., Margas, M., Makowska, K., and Lejman, M. (2022). Insights into Modern Therapeutic Approaches in Pediatric Acute Leukemias. Cells, 11.","DOI":"10.3390\/cells11010139"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/0167-5699(94)90276-3","article-title":"CD20: A regulator of cell-cycle progression of B lymphocytes","volume":"15","author":"Tedder","year":"1994","journal-title":"Immunol. Today"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1182\/blood-2002-02-0513","article-title":"Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX","volume":"100","author":"Krackhardt","year":"2002","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/leu.2014.188","article-title":"Basal Ca(2+) signaling is particularly increased in mutated chronic lymphocytic leukemia","volume":"29","author":"Muggen","year":"2015","journal-title":"Leukemia"},{"key":"ref_121","first-page":"225","article-title":"Targeting CD19 in B-cell lymphoma: Emerging role of SAR3419","volume":"5","author":"Raufi","year":"2013","journal-title":"Cancer Manag. Res."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.imlet.2017.01.010","article-title":"CD19, from bench to bedside","volume":"183","author":"Li","year":"2017","journal-title":"Immunol. Lett."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1080\/13543784.2021.1928074","article-title":"Investigational immunotherapy targeting CD19 for the treatment of acute lymphoblastic leukemia","volume":"30","author":"Viardot","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1080\/13543784.2018.1492549","article-title":"CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas","volume":"27","author":"Watkins","year":"2018","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"22","DOI":"10.4161\/mabs.22771","article-title":"Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties","volume":"5","author":"Klein","year":"2013","journal-title":"MAbs"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.2147\/IJN.S139450","article-title":"CPX-351: A nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties","volume":"14","author":"Mayer","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1634\/theoncologist.2015-0391","article-title":"Efficacy and Safety of Vincristine Sulfate Liposome Injection in the Treatment of Adult Acute Lymphocytic Leukemia","volume":"21","author":"Douer","year":"2016","journal-title":"Oncologist"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Talens-Visconti, R., Diez-Sales, O., de Julian-Ortiz, J.V., and Nacher, A. (2022). Nanoliposomes in Cancer Therapy: Marketed Products and Current Clinical Trials. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23084249"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/9\/1965\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:33:34Z","timestamp":1760142814000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/9\/1965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,17]]},"references-count":129,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["pharmaceutics14091965"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14091965","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,17]]}}}